Exelixis PE ratio EXEL

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: 20.3×
9-year median: 22.8×
Against its 9-year history: 42nd; percentile: 0 is its lowest day, 100 its highest
9-year range: 8.0× to 128×
Peer median: 37.6×

Exelixis' PE ratio is 20.3× as of Oct 23, 2026: a share price of $64.53 against $3.18 of earnings per share over the last twelve months.

That is below its 9-year median of 22.8×, close to the middle of its last 9 years.

Over that time it ranged from 8.0× in Oct 2019 to 128× in May 2021.

The median for 10 biotech stocks of a similar size is 37.6×.

PE ratio over time

median 22.8×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.3×	14.9×	20.3×
2025	19.5×	17.2×	23.2×
2024	21.7×	21.3×	83.0×
2023	85.7×	17.3×	85.7×
2022	16.9×	16.6×	38.4×
2021	35.8×	31.1×	128×
2020	41.8×	8.7×	43.1×
2019	9.3×	8.0×	20.1×
2018	16.5×	14.0×	50.3×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	n/m a value too high to mean anything
2012	9.2×	7.5×	10.9×

Against its peers

Companies in Biotechnology nearest Exelixis' size, closest first, today.

Company	PE ratio
EXELExelixis	20.3×
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
TECHBIO-TECHNE	63.1×
INCYIncyte	14.7×
UTHRUnited Therapeutics	21.0×
RGENRepligen	242×
KRYSKrystal Biotech	39.0×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	67.6×
REGNRegeneron Pharmaceuticals	19.9×
Peer median	37.6×

Where Exelixis ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Exelixis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.